Loading…
Lantheus Holdings completed its merger with Progenics Pharmaceuticals, an oncology company. Progenics stockholders received 0.31 shares of Lantheus common stock and a contingent value right per share.
Curium US Holdings agreed to acquire Lantheus for $102.50 per share in cash at closing plus up to $12.00 per share in contingent value rights, for a total transaction value of up to $8.0 billion.
Lantheus Holdings and GE Healthcare signed a definitive license agreement for the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational PET MPI agent. GE Healthcare will lead and fund development and have exclusive worldwide commercialization rights.